Steven Bellon
Chief Tech/Sci/R&D Officer at FOGHORN THERAPEUTICS INC.
Net worth: 1 M $ as of 31/03/2024
Profile
Steven F.
Bellon is currently the Chief Scientific Officer at Foghorn Therapeutics, Inc. He previously worked as the Executive Director & Head-Structural Biology at Constellation Pharmaceuticals, Inc. from 2008 to 2016.
Dr. Bellon holds a doctorate degree from the Massachusetts Institute of Technology, which he obtained in 1992.
He also has an undergraduate degree from Haverford College, which he received in 1987.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 29/02/2024 | 171,957 ( 0.40% ) | 1 M $ | 31/03/2024 |
Steven Bellon active positions
| Companies | Position | Start |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 10/01/2022 |
Former positions of Steven Bellon
| Companies | Position | End |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 01/05/2016 |
Training of Steven Bellon
| Massachusetts Institute of Technology | Doctorate Degree |
| Haverford College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Steven Bellon
